Acquisition a Key Component in the Development of Complete
Sample-to-Answer Solutions for Next-Generation Sequencing
SAN DIEGO--(BUSINESS WIRE)--Jul. 23, 2013--
Illumina, Inc. (NASDAQ:ILMN) today announced that it has acquired
Advanced Liquid Logic (ALL), a leading provider of liquid handling
solutions. ALL, now a wholly owned subsidiary of Illumina, has developed
a proprietary “digital microfluidics” technology based on electrowetting
that precisely manipulates small droplets within a sealed disposable
cartridge to perform complex laboratory protocols. This proven
technology will enable Illumina to deliver the simplest and most
efficient sample-to-answer next-generation sequencing (NGS) workflow.
“For our research customers, ALL’s technology will further streamline
the industry's simplest NGS workflow, while for clinical and applied
markets, where ease of use and consistency are especially valued, it
will allow us to offer integrated, end-to-end solutions,” said Christian
Henry, Senior Vice President and General Manager of Illumina’s Genomic
Solutions business. “ALL brings an impressive IP portfolio in digital
microfluidics and a talented team with a track record of innovation.”
One of Illumina's goals is to provide customers with a holistic set of
tools to go from biological sample to answer quickly and easily,
minimizing the risk of errors and reducing hands-on time in the lab. To
that end, Illumina recently announced it is collaborating with leading
vendors of liquid handling robotic platforms to make automation
solutions for high-throughput sample preparation more accessible. With
its acquisition of ALL, Illumina will be able to introduce similar
benefits to its low- and mid-throughput customers.
ALL’s versatile technology has been demonstrated across numerous
applications, including nucleic acid isolation from various sample types
and library generation for next-generation sequencing. Its robust
solution has a clear advantage in precisely handling low sample volumes,
which is an increasingly important focus for customers.
For more information about ALL’s technology, visit www.liquid-logic.com/technology.
is a leading developer, manufacturer, and marketer of life science tools
and integrated systems for the analysis of genetic variation and
function. We provide innovative sequencing and array-based solutions for
genotyping, copy number variation analysis, methylation studies, gene
expression profiling, and low-multiplex analysis of DNA, RNA, and
protein. We also provide tools and services that are fueling advances in
consumer genomics and diagnostics. Our technology and products
accelerate genetic analysis research and its application, paving the way
for molecular medicine and ultimately transforming healthcare.
This release may contain forward looking statements that involve risks
and uncertainties. Important factors that could cause actual results to
differ materially from those in any forward-looking statements are
detailed in our filings with the Securities and Exchange Commission,
including our most recent filings on Forms 10-K and 10-Q, or in
information disclosed in public conference calls, the date and time of
which are released beforehand. We do not intend to update any
forward-looking statements after the date of this release.
Source: Illumina, Inc.